Cash from financing is the cash generated/spent from financial activities such as share issuance (buy back), debt issuance (repayment), and dividends paid to preferred and common stockholders.
For the
three
months ended in Mar. 2026,
Abbott Laboratories paid$180 Mil more to buy back shares than it received from issuing new shares.
It received$18,475 Mil from issuing more debt.
It paid$0 Mil more to buy back preferred shares than it received from issuing preferred shares.
It spent$1,098 Mil paying cash dividends to shareholders.
It received$116 Mil on other financial activities.
In all, Abbott Laboratoriesearned$17,313 Mil on financial activities for the
three
months ended in Mar. 2026.
Abbott Laboratories (NYSE:ABT) Cash Flow from Financing Explanation
Cash from financing contains six items:
1. Issuance of Stock:
A company may raise cash from issuing new shares. Issuance of stock represents the cash inflow from offering common stock, which is the additional capital contribution to the entity during the period.
Abbott Laboratories's issuance of stock for the
three
months ended in Mar. 2026 was $0 Mil.
2. Repurchase of Stock:
A company may raise cash from issuing new shares. It can also use cash to buy back shares. Repurchase of stock represents the cash outflow to reacquire common stock during the period.
Abbott Laboratories's repurchase of stock for the
three
months ended in Mar. 2026 was $-180 Mil.
3. Net Issuance of Debt:
Net issuance of debt is the cash a company received or spent through debt related activities such as debt issuance or debt repayment. If a company pays down its debt during the period, this number will be negative. If a company issued more debt, it receives cash and this number is positive.
Abbott Laboratories's net issuance of debt for the
three
months ended in Mar. 2026 was $18,475 Mil.
Abbott Laboratories received$18,475 Mil from issuing more debt.
4. Net Issuance of Preferred Stock:
A company may raise cash from issuing new preferred shares. It can also use cash to buy back preferred shares. If this number is positive, it means that the company has received more cash from issuing preferred shares than it has paid to buy back preferred shares. If this number is negative, it means that company has paid more cash to buy back preferred shares than it has received for issuing preferred shares.
Abbott Laboratories's net issuance of preferred for the
three
months ended in Mar. 2026 was $0 Mil.
Abbott Laboratories paid$0 Mil more to buy back preferred shares than it received from issuing preferred shares.
5. Cash Flow for Dividends:
Cash flow for dividends refers to the payment of cash to shareholders as dividends when the company generates income.
Abbott Laboratories's cash flow for dividends for the
three
months ended in Mar. 2026 was $-1,098 Mil.
Abbott Laboratories spent$1,098 Mil paying cash dividends to shareholders.
6. Other Financing:
Money spent or earned by company from other financial activities.
Abbott Laboratories's other financing for the
three
months ended in Mar. 2026 was $116 Mil.
Abbott Laboratories received$116 Mil on other financial activities.
Abbott Laboratories Cash Flow from Financing Related Terms
Abbott Laboratories Cash Flow from Financing Historical Data
* Premium members only.
The historical data trend for Abbott Laboratories's Cash Flow from Financing can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Abbott Laboratories Cash Flow from Financing Chart
Abbott Laboratories Cash Flow from Financing Calculation
This is the cash generated/spent from financial activities such as share issuance (buy back), debt issuance (repayment), and dividends paid to preferred and common stockholders. In the calculation of free cash flow, cash from financing is not calculated because it is not related to operating activities.
Abbott Laboratories's Cash from Financing for the fiscal year that ended in Dec. 2025 is calculated as:
Cash Flow from Financing for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $13,059 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
What does a Cash Flow from Financing of $13,059 Mil mean?
Abbott Laboratories (ABT) has a Cash Flow from Financing of $13,059 Mil as of Mar. 2026. Cash Flow from Financing is the amount of cash earned or paid from financing operations. View historical data for Abbott Laboratories and its competitors.
Is Abbott Laboratories' Cash Flow from Financing too high?
Abbott Laboratories' current Cash Flow from Financing is $13,059 Mil. Overall, Abbott Laboratories has a GF Score™ of 76/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Abbott Laboratories' Cash Flow from Financing compare to SYK and MDT?
Abbott Laboratories' Cash Flow from Financing of $13,059 Mil can be compared against companies in the Medical Devices & Instruments industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Cash Flow from Financing for a Medical Devices & Instruments company?
A good Cash Flow from Financing depends on the Medical Devices & Instruments industry context. However, Cash Flow from Financing should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Cash Flow from Financing mean?
A high Cash Flow from Financing can signal that a stock is expensive relative to its fundamentals. Cash Flow from Financing is the amount of cash earned or paid from financing operations. View historical data for Abbott Laboratories and its competitors. Abbott Laboratories's current Cash Flow from Financing is $13,059 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Abbott Laboratories stock overvalued right now?
Based on GuruFocus' analysis, Abbott Laboratories (ABT) is currently considered Modestly Undervalued. The stock's GF Value™ is $130.40, compared to a current price of $93.93 — trading 28% below its estimated fair value. The current Cash Flow from Financing is $13,059 Mil. Abbott Laboratories' overall GF Score™ is 76/100. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Cash Flow from Financing calculated?
Cash Flow from Financing is calculated from a company's financial statements. For Abbott Laboratories (ABT), the current Cash Flow from Financing is $13,059 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Abbott Laboratories (ABT) Overvalued in 2026?
Based on GuruFocus' analysis, Abbott Laboratories stock appears to be undervalued.
The current stock price of $93.93 is trading 28% below its estimated GF Value™ of $130.40.
GuruFocus considers Abbott Laboratories to be Modestly Undervalued.
Key valuation signals for ABT:
Cash Flow from Financing: $13,059 Mil
GF Value™: $130.40 vs. price of $93.93 (28% below fair value)
No single metric tells the full story. See the ABT stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Abbott manufactures and markets cardiovascular and diabetes devices, adult and pediatric nutritional products, diagnostic equipment and testing kits, and branded generic drugs. Products include pacemakers, implantable cardioverter defibrillators, neuromodulation devices, coronary stents, catheters, infant formula, nutritional liquids for adults, continuous glucose monitors, and immunoassays and point-of-care diagnostic equipment. Abbott derives roughly 60% of sales outside the United States.
76GF Score
Get the complete analysis for ABT
Cash Flow from Financing is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ABT has been successfully added to your 
